Business ❯ Pharmaceuticals ❯ Biotechnology

Drug Discovery

Artificial Intelligence

Takeda and Nabla Bio Expand AI Protein-Design Deal With Potential Payouts Above $1 Billion

The deal reflects Takeda's pivot toward scalable AI-enabled discovery after exiting cell therapy.